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We employed Cre/loxP technology to generate
mPDK1±/± mice, which lack PDK1 in cardiac muscle.
Insulin did not activate PKB and S6K, nor did it
stimulate 6-phosphofructo-2-kinase and production of
fructose 2,6-bisphosphate, in the hearts of mPDK1±/±
mice, consistent with PDK1 mediating these processes.
All mPDK1±/± mice died suddenly between 5 and
11 weeks of age. The mPDK1±/± animals had thinner
ventricular walls, enlarged atria and right ventricles.
Moreover, mPDK1±/± muscle mass was markedly
reduced due to a reduction in cardiomyocyte volume
rather than cardiomyocyte cell number, and markers
of heart failure were elevated. These results suggested
mPDK1±/± mice died of heart failure, a conclusion sup-
ported by echocardiographic analysis. By employing a
single-cell assay we found that cardiomyocytes from
mPDK1±/± mice are markedly more sensitive to
hypoxia. These results establish that the PDK1 sig-
nalling network plays an important role in regulating
cardiac viability and preventing heart failure. They
also suggest that a de®ciency of the PDK1 pathway
might contribute to development of cardiac disease in
humans.
Keywords: cardiac muscle/heart failure/hypoxia/PDK1/
PI 3-kinase/PKB/Akt
Introduction
Hormones and growth factors trigger the activation of
members of a group of protein kinases including protein
kinase B (PKB) and p70 ribosomal S6K (S6K), which
belong to the AGC family of protein kinases (Brazil and
Hemmings, 2001; Lawlor and Alessi, 2001; Newton,
2002). The 3-phosphoinositide-dependent protein kinase-1
(PDK1) plays a central role in activating these AGC kinase
members by phosphorylating these enzymes at their
activation loop (Toker and Newton, 2000; Alessi, 2001).
Much research has shown that the PDK1/AGC kinase-
signalling pathway regulates diverse cellular processes,
such as those relevant to cell survival, proliferation and
metabolic responses to insulin. Misregulation of AGC
kinase members is thought to contribute to many diseases.
For example, hyperactivation of this pathway is implicated
in inducing cardiac hypertrophy (Sugden, 2001) and
promoting the survival and proliferation of a signi®cant
number of cancers (Simpson and Parsons, 2001). A
de®ciency in the activation of AGC kinases may be a
primary cause of the insulin-resistant form of diabetes
(Saltiel and Kahn, 2001), as well as neuronal cell death
following a stroke (Wick et al., 2002).
The activation of PKB and S6K isoforms by insulin and
growth factors, as well as being dependent on PDK1,
requires the prior activation of the phosphoinositide 3-
kinase (PI 3-kinase) (Vanhaesebroeck et al., 2001).
This produces the second messenger, phosphatidyl-
inositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3], which
binds to the pleckstrin homology domains of PKB and
PDK1, recruiting these enzymes to the plasma membrane
where PKB is activated by phosphorylation of its
activation-loop residue (Thr308 in PKBa) by PDK1
(Brazil and Hemmings, 2001; Scheid and Woodgett,
2001). PtdIns(3,4,5)P3 also stimulates the phosphorylation
of PKB at its hydrophobic motif residue (Ser473 in
PKBa), which is required for maximal activation of PKB
(Alessi et al., 1996; Yang et al., 2002), by an as yet
unknown mechanism. In contrast, S6K does not interact
with PtdIns(3,4,5)P3 but, instead, PtdIns(3,4,5)P3 stimu-
lates, by a not completely characterized mechanism, the
phosphorylation of the hydrophobic motif residue (Thr389
in S6K1) (Avruch et al., 2001; Volarevic and Thomas,
2001). This generates a binding site for PDK1 to interact
with, phosphorylate and activate S6K (Biondi et al., 2001,
2002; Frodin et al., 2002; Collins et al., 2003).
The key role that PDK1 plays in activating certain AGC
kinase members in mammalian cells was established by the
®nding that in mouse embryonic stem (ES) cells lacking
PDK1, PKB and S6K could not be activated (Williams
et al., 2000). Moreover, genetic analysis in Saccharomyces
cerevisiae (Casamayor et al., 1999; Inagaki et al., 1999),
Saccharomyces pombe (Niederberger and Schweingruber,
1999), Drosophila (Cho et al., 2001c; Rintelen et al., 2001)
and Caenorhabditis elegans (Paradis et al., 1999) supports
the conclusion that PDK1 is required for the activation of
PKB and S6K homologues, as well as being necessary for
the viability and development of these model organisms.
We have also recently provided evidence that PDK1 is
essential for mammalian development, as mice lacking
PDK1 die at day E9.5 of embryogenesis due to multiple
abnormalities (Lawlor et al., 2002). In this study, to
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learn more about the roles that PDK1 plays after birth/
development, we have generated and analysed the cardiac
phenotype of mice that lack PDK1 in skeletal and heart
muscle.
Results
Generation of mice lacking PDK1 in heart
We previously described (Lawlor et al., 2002) the
generation of PDK1¯Dneo/¯Dneo mice in which exons 3 and
4 of the PDK1 gene were ¯anked with the loxP CRE
excision sequence (Figure 1A). These mice, in which
PDK1 was expressed in all tissues at the same level as in
wild-type mice, were crossed with transgenic mice
expressing the CRE recombinase under the muscular
creatine kinase promoter which induces expression of this
enzyme speci®cally in skeletal muscle and heart just
prior to birth (Bruning et al., 1998). In the resulting
PDK1¯Dneo/¯Dneo mice that express the CRE recombinase
(termed mPDK1±/± mice), exons 3 and 4 of the PDK1
would be speci®cally excised in skeletal and cardiac
muscle, thereby ablating functional PDK1 expression, as
this truncation prevents translation of the entire kinase and
pleckstrin homology domains (Williams et al., 2000).
mPDK1±/± mice were born at the expected Mendelian
frequency (Figure 1B), and the littermate PDK1¯Dneo/¯Dneo
mice not expressing CRE (termed mPDK1+/+) were
utilized as the control animals throughout this study.
As expected, the mPDK1±/± mice displayed no signi®-
cant expression of the PDK1 protein in six different
muscles studied, including heart (Figure 1C). In contrast,
expression of PDK1 in liver, adipose and brain was
identical to the level found in the control mPDK1+/+ mice.
Survival of mPDK1±/± mice
Up to the age of 5 weeks, the mPDK1±/± mice survived
normally (Figure 1D), were apparently healthy, displaying
no abnormal phenotype, and their growth, as assessed by
body weight, was indistinguishable from that of mPDK1+/+
littermates (Supplementary ®gure 1, available at The
EMBO Journal Online). The mPDK1±/± mice breath, eat
normally and display the same physical activity as
mPDK1+/+ mice. We also measured fasting blood glucose
levels in mice up to 8 weeks of age and observed no
signi®cant difference between mPDK1+/+ and mPDK1±/±
animals (data not shown), indicating that these mice were
not markedly diabetic. However, between the ages of 5
and 11 weeks of age, 100% of the mPDK1±/± mice died,
whereas the mPDK1+/+ littermates survived as expected
(Figure 1D). In all cases, the mice were noticeably less
active 2±3 days before they died, and a signi®cant
reduction in body weight was observed (Supplementary
®gure 1). Before this, there were no noticeable differences
between mPDK1+/+ and mPDK1±/± mice. There was also
no signi®cant difference in the ages at which male and
female mice died (data not shown).
Evidence that mPDK1±/± mice develop
heart failure
Post-mortem analysis of the mPDK1±/± mice revealed that
the hearts of these animals were signi®cantly enlarged,
with blood clots found in both atria, which also appeared
massively in¯ated. Morphological analysis of other
organs (data not shown) of the mPDK1±/± mice, including
skeletal muscle (Supplementary ®gure 2), presented no
evidence of any abnormality. These observations sug-
gested that a lack of PDK1 in cardiac muscle could be
inducing heart failure leading to death of the animals. To
investigate this in more detail, we performed histological
analysis on hearts derived from mPDK1±/± and mPDK1+/+
Fig. 1. Generation and survival of mice lacking PDK1 in skeletal
muscle and heart. (A) Diagram illustrating the positions of exons 2±5
and the loxP Cre excision sites of the ¯oxed PDK1 gene. The positions
of the PCR primers used to genotype mice described in the Materials
and methods are indicated with arrows. (PDK1¯Dneo/¯Dneo), allele with
the loxP sites ¯anking exons 3 and 4 without the neomycin resistance
cassette; (PDK1±/±), the allele in which exon 3 and 4 have been
removed by Cre recombinase resulting in the ablation of the expression
of PDK1 beyond exon 2, which includes the kinase and pleckstrin
homology domain (Williams et al., 2000). (B) Breeding strategy used
for the generation of mice lacking PDK1 in skeletal muscle and heart,
where MckCre denotes transgenic mice expressing the Cre recombinase
under the muscular creatine kinase promoter. Note that throughout this
study, PDK1¯Dneo/¯DneoMckCre+/± mice are termed mPDK1±/± and
PDK1¯Dneo/¯DneoMckCre±/± are termed mPDK1+/+. (C) PDK1 was af®nity
puri®ed from the indicated tissues using PIF±Sepharose (as described
in the Materials and methods), electrophoresed on a 10% SDS±poly-
acrylamide gel and immunoblotted with anti-PDK1 antibody. It should
be noted that as observed in previous studies (Lawlor et al., 2002;
Collins et al., 2003), PDK1 migrates as a doublet, although the reason
for this is not known. Abbreviations used are (Qua), quadriceps;
(Gastr), gastrocnemius; (Ext), extensor digitalis; and (Dia), diaphragm.
Similar results were obtained in three separate experiments using
different mice of 5±6 weeks of age. Direct immunoblotting of cell
lysates with PDK1 antibody revealed identical ®ndings except that
PDK1 immuno-reactive bands were of lower intensity (data not
shown). (D) The indicated number of male and female mice were main-
tained under standard husbandry conditions and the percentage of
surviving mice of each age is indicated. (n) denotes the number of each
genotype.
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mice of 2, 4 and 6 weeks of age, as well as on hearts from
mPDK1±/± animals after death. This analysis revealed that
the mPDK1±/± hearts were slightly smaller at 2 weeks of
age (Figure 2A), the thickness of the ventricular walls was
normal and the atria of normal size (Figure 2B). Moreover,
analysis of cardiac tissue of 2-week-old mice, revealed no
evident abnormalities or signi®cant differences in cardio-
myocyte size (Figure 2C). By 4 weeks of age, the
difference in size between the mPDK1±/± and mPDK1+/+
hearts was more obvious (Figure 2D), but no major
abnormality was noticeable in the ventricular walls
(Figure 2E) or cardiac tissue (Figure 2F). By 6 weeks of
age, however, the mPDK1±/± hearts were markedly smaller
(Figure 2G), the ventricle walls were signi®cantly thinner
(Figures 2H and 3A) and the atria enlarged compared with
control mPDK1+/+ heart (Figure 2H). Strikingly, the right
ventricle was signi®cantly enlarged in mPDK1±/± hearts,
while the overall size of the left ventricle was similar but
the muscle walls were much thinner (Figures 2H and 3A).
Additionally, in the cardiac tissue, the cardiomyocytes
appeared more separated from each other and possibly
slightly smaller (Figure 2I). After death, the mPDK1±/±
hearts were enlarged and appeared bigger than control
mPDK1+/+ hearts (Figure 2J). Moreover, at this stage, the
ventricular walls of the mPDK1±/± hearts were vastly
thinner (Figure 2K). Post-mortem analysis of mPDK1±/±
hearts con®rmed that cardiac tissue had signi®cantly
expanded, resulting in marked separation of myocytes
(Figure 2L). We were unable to detect myocyte disarray in
mPDK1±/± hearts at any age, including after death
(Supplementary ®gure 3).
In vivo echocardiographic analysis in mPDK1±/±
mice
Echocardiographic analysis of 5- to 6-week-old mPDK1±/±
mice revealed the development of heart failure, re¯ected in
a reduction in both fractional shortening and ejection
fraction (Figure 3B). Thinning of the left ventricle was
also con®rmed by a signi®cant reduction in the posterior
wall thickness measured during diastole (Figure 3B). At
this stage, there was no evidence for an increase in left
ventricular dimension, although an enlarged right ventricle
was visible in some of the echocardiographic images.
Quantitative analysis of muscle mass,
cardiomyocyte volume and number
In order to further characterize the cardiac phenotype of
mPDK1±/± mice, we employed rigorous unbiased methods
for determining total muscle mass, average cardiomyocyte
volume and total cardiomyocyte number. The muscle mass
was calculated using the Cavalieri method, whereas the
cardiomyocyte volume and cardiomyocyte number in
Fig. 2. Histological analysis of hearts from mPDK1+/+ and mPDK1+/+ mice. At the indicated times the hearts were ®xed in 10% formalin, embedded in
wax and stained with haematoxilin and eosin. (A, D, G and J) Comparison of a representative image of heart of littermate mPDK1±/± and mPDK1+/+
mice of the same sex, before the ®xation and staining. (B, E, H and K) Representative longitudinal sections after ®xation and staining. (C, F, I and L)
Representative micrographs of transversal sections of the muscular ®bres. Scale bar is shown at the bottom of each set of panels.
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the heart tissue were determined using a stereological
approach called the dissector principle (Sterio, 1984;
Gunderson, 1986). The muscle mass of mPDK1±/± hearts
was signi®cantly reduced and the difference in muscle
mass between mPDK1±/± and mPDK1+/+ hearts increased
with age (Figure 4A). The number of cardiomyocytes in
the mPDK1±/± and mPDK1+/+ hearts was similar at all ages
(Figure 4B). The average estimated volume of mPDK1±/±
cardiomyocytes was signi®cantly lower and the difference
in volume between mPDK1±/± and mPDK1+/+ myocytes
increased with age (Figure 4C). These ®ndings show that a
reduced cardiomyocyte volume rather than a decrease in
cell number caused the reduction in muscle mass of the
mPDK1±/± hearts.
Interestingly, histological analysis of the quadriceps of
skeletal muscle of 6-weeks-old mPDK1±/± and mPDK1+/+
mice revealed no signi®cant reduction in muscle ®bre
diameter (Supplementary ®gure 2). As muscle ®bres are
formed from fused cells, it is dif®cult to assess whether the
®bres are formed from a larger number of smaller cells or
whether limb skeletal muscle cells lacking PDK1 are not
reduced in cell size.
Further evidence of cardiomyopathy in mPDK1±/±
mice
Disease progression in cardiomyopathy in humans can
result primarily from myocardial injury and hypertension,
as well as genetic factors, causing a marked increase in
cardiac chamber volume and separation of cardiomyo-
cytes. This leads to the accumulation of collagen in the
intracellular space (Crackower et al., 2002b). We therefore
measured the collagen content of the mPDK1±/± and
mPDK1+/+ hearts using the quantitative Cavalieri method
and a collagen speci®c stain. At weeks 2 and 4, mPDK1±/±
and mPDK1+/+ hearts contained similar levels of collagen
(Figure 5A). However, by 6 weeks of age and after death,
the collagen content in the mPDK1±/± hearts was markedly
elevated compared with control mPDK1+/+ hearts. Another
key feature of heart failure is the reactivation of an
embryonic gene programme (Hunter and Chien, 1999).
The mRNA levels of both the atrial natriuretic factor and
b-myosin heavy chain, two embryonic genes used as
molecular markers of heart failure (Crackower et al.,
Fig. 3. Echocardiographic analysis of mPDK1±/± hearts. (A) Repre-
sentative transversal section of 6-week-old mPDK1±/± and mPDK1+/+
mouse heart ®xed in 10% formalin, embedded in wax and stained with
haematoxylin and eosin. rv, right ventricle; lv, left ventricle.
(B) Echocardiographic analysis of 5- to 6-week-old mPDK1+/+ and
mPDK1±/± mice. LVEDD, left ventricle end diastolic dimensions;
LVESD, left ventricle end systolic dimensions; LVareaED, left
ventricle area end diastolic; LvareaSD, left ventricle area end systolic;
PWD, posterior wall diastolic thickness; PWS, posterior wall systolic
thickness; FS, fractional shortening; EF, ejection fraction; BW, body
weight; LVEDD/BW, left ventricular end-diastolic dimension corrected
for body weight. Data are presented as the mean 6 SEM and were
compared by Student's t-test, n = 11 for mPDK+/+ and 9 for mPDK±/±.
Fig. 4. Quantitative analysis of muscle mass, cardiomyocyte volume
and number. (A) The muscle mass of mPDK1+/+ and mPDK1±/± hearts
of the indicated ages or after death. The results shown were determined
by the Cavalieri method and presented as the average volume 6 SD of
the results obtained from analysing three separate hearts of each age
and genotype. The cardiomyocyte volume (B) and cardiomyocyte
number (C) were determined using the dissector principle. The cardio-
myocyte number was determined by calculating the nuclei number,
assuming one nuclei per cardiomyocyte. The data are presented as the
mean 6 SD of three separate hearts of each age and genotype.
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2002b), were found to be signi®cantly increased in the
hearts derived from 6-week-old mPDK1±/± mice
(Figure 5B).
The p38 mitogen activated protein kinase has been
reported to play a role in regulating myocardial cell
growth. p38 is partially activated in normal hearts and is
further stimulated by diverse hypertrophic insults (Behr
et al., 2001). Moreover, it has also been reported that p38
is inactivated in failing human heart (Communal et al.,
2002). We therefore assessed p38 activity using a
phosphospeci®c antibody and found that in 6-week-old
mPDK1±/± hearts, p38 phosphorylation was markedly
reduced compared with control mPDK1+/+ hearts
(Figure 5C, upper panel), consistent with the notion that
p38 activity might be down regulated in the failing heart.
The phosphorylation of other MAP kinase members,
ERK1/ERK2 (Figure 5C, lower panel) and JNK1/JNK2
(data not shown) was similar in 6-week-old mPDK1±/± and
mPDK1+/+ hearts. A characteristic feature of cardiomyo-
pathy, termed dilated cardiomyopathy, is an increase in the
Fig. 5. Analysis of markers of heart failure. (A) Histological sections of mPDK1+/+ and mPDK1±/± hearts of the indicated ages or after death were
stained with Picric-Sirius Red dye, which stains collagen in red. The amount of collagen present in these sections was quanti®ed using the Cavalieri
method. The data are presented as the mean 6 SD of three separate hearts of each age and genotype. Representative micrographs of Picric-Sirius Red-
stained 6-week-old mPDK1±/± and mPDK1+/+ heart sections are shown. (B) RNA was isolated from mPDK1±/± and mPDK1+/+ hearts of 6 weeks of
age, and RT±PCR analysis, described in the materials and methods, was employed to assess the mRNA expression levels of atrial natriuretic factor
(ANF), b-myosin heavy chain (b-MHC) and 18S ribosomal RNA (18S) as a control. Each lane on the agarose gel represents a different mouse.
(C) Cell extracts were prepared from mPDK1±/± and mPDK1+/+ hearts of 6 weeks of age and immunoblotted with the indicated antibodies. Each lane
on the immunoblot represents a different mouse. (D) Electron microscope sections of mPDK1+/+ and mPDK1±/± hearts of the indicated ages. The
Z-line thickness was quantitated by counting 135 randomly derived Z-lines from three hearts of each genotype and age. The data are presented as
average thickness 6 SD.
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Z-line thickness in sarcomeres resulting from over-
stretching of cardiac muscle (Knoll et al., 2002). We
therefore measured Z-line thickness, using electron
microscopy, of mPDK1±/± mice, normal-weight mice
(~6 weeks old) and mice that had started to lose weight
(~8 weeks old) and were predicted to die soon. This
analysis revealed that at 6 weeks of age there was no
signi®cant difference in Z-line thickness but by 8 weeks of
age the Z-line was found to be signi®cantly thicker in the
mPDK1±/± mice (Figure 5D). The structure, length and
organization of the mPDK1±/± and mPDK1+/+ sacromeres
was found to be similar in mice of up to 6 weeks of age.
Analysis of PKB and S6K activation in mPDK1+/+
and mPDK1±/± hearts
To determine whether lack of expression of PDK1 in heart
impaired activation of characterized PDK1 substrates,
mPDK1±/± and control mPDK1+/+ mice were injected with
insulin for varying times and heart extracts generated.
Activity of PKB (Figure 6A) and S6K (Figure 6B) was
Fig. 6. Activation of PKB, S6K and PFK2 in heart by insulin. Mice were fasted overnight and injected with either saline for 10±20 min (for the 0 time
point control) or 1 mU/g of insulin for the indicated times. The heart was then rapidly extracted and frozen in liquid nitrogen. PKB (A) or S6K (B)
were immunoprecipitated from cardiac extract and the activity determined using a quantitative peptide phosphorylation assay. Each point represents
the mean activity 6 SD of three different hearts with each assayed in triplicate. (C and D) As above except that cell lysates form the indicated hearts
were immunoblotted with the indicated antibodies. Each lane represents a different mouse PFK-2 activity (E) and fructose-2,6-bisphosphate (Fru-2,6-
P2) levels (F) were measured as described in the Materials and methods. Each point represents the mean activity 6 SD of three to ®ve different hearts
with each assayed in duplicate.
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measured by a quantitative immunoprecipitation kinase
assay. In hearts derived from mPDK1+/+ mice, insulin
induced a 10-fold activation of PKB within 5 min and a
6-fold activation of S6K within 20 min. The low basal
activity of PKB and S6K in unstimulated mPDK1±/± hearts
was similar to that observed in mPDK1+/+ mice, but was
not further activated by insulin.
In Figure 6C, the activation of PKB was also assessed
using phosphospeci®c antibodies raised against the site of
PDK1 phosphorylation (Thr308) as well as the hydro-
phobic motif phosphorylation site (Ser473), which is
thought to be phosphorylated independently of PDK1.
Insulin induced Thr308 phosphorylation of PKB in
mPDK1+/+ hearts within 2 min, but as expected, no
phosphorylation of Thr308 was detected in insulin-treated
mPDK1±/± hearts at any time point tested. In unstimulated
mPDK1+/+ hearts, PKB is not phosphorylated at Ser473
and insulin induced a marked phosphorylation of this
residue (Figure 6C). In contrast, in unstimulated
mPDK1±/± hearts, PKB was markedly phosphorylated at
Ser473, to a level similar to that observed in insulin-
stimulated mPDK1+/+ hearts. Stimulation of mPDK1±/±
mice with insulin only induced a small additional increase
in phosphorylation of PKB at Ser473. Similar ®ndings
have been made in mouse ES cells lacking PDK1
(Williams et al., 2000) and suggest that there may be
some cross-talk between the regulation of the as yet
uncharacterized PKB Ser473 kinase and PDK1.
The hydrophobic motif phosphorylation site on S6K
(Thr389) plays a key role in regulating the activation of
this kinase (Pearson et al., 1995). Recent work by several
groups suggested that phosphorylation of Thr389 is
regulated by PKB-catalysed phosphorylation of the
tuberin tumour suppressor protein, and also involves
mTOR (reviewed in McManus and Alessi, 2002).
Consistent with this notion and the lack of PKB activity
in mPDK1±/± hearts, insulin failed to stimulate S6K
phosphorylation at Thr389 in mPDK1±/± hearts
(Figure 6D). In contrast, in mPDK1+/+ hearts, insulin
stimulated a marked phosphorylation of Thr389 within
10±20 min. Moreover, insulin also induced the phos-
phorylation of the PKB substrates GSK3a and GSK3b
(Figure 6C) and the S6K substrate ribosomal S6 protein
(Figure 6D), in mPDK1+/+ hearts but not in mPDK1±/±
hearts.
Genetic evidence that PDK1 mediates insulin
activation of 6-phosphofructo-2-kinase
The heart adapts its energy consumption to the availability
of substrates and hormones. Under normal conditions,
fatty acids are preferred to glucose. Hormones like insulin
modify this hierarchy. Insulin inhibits fatty acid oxidation
and stimulates glucose consumption (Hue et al., 2002).
Stimulation of heart glycolysis by insulin is thought to be
mediated through glucose transporter translocation and
activation of 6-phosphofructo-2-kinase (PFK-2), which
generates fructose 2,6-bisphosphate, the allosteric activ-
ator of 6-phosphofructo-1-kinase, a key enzyme of
glycolysis (Depre et al., 1998; Hue et al., 2002). PFK-2
is activated in vivo by phosphorylation of Ser466 and
Ser483 lying in an AGC kinase phosphorylation motif
(Bertrand et al., 1999). In vitro Ser466 and Ser483 are
phosphorylated by several AGC kinases including PKB
(Deprez et al., 1997). In vivo phosphorylation of these sites
is induced by insulin and this phosphorylation is prevented
by treatment of cells with PI 3-kinase inhibitors, but it is
not yet clear whether PKB or another insulin-stimulated
wortmannin-sensitive kinase mediates this phosphoryl-
ation in vivo (Deprez et al., 2000). In order to assess the
role of PDK1 in regulating activation of PFK-2, mPDK1+/+
and mPDK1±/± mice were injected with insulin and at
varying times hearts extracted and PFK-2 activity
(Figure 6E) and fructose 2,6-bisphosphate levels
(Figure 6F) measured. In mPDK1+/+ mice, PFK-2 activity
was stimulated nearly 2-fold within 5 min of insulin
injection and accumulation of fructose 2,6-bisphosphate
was detected after 10 min, reaching ~5-fold higher levels
than in unstimulated mPDK1+/+ hearts after 20 min. In the
mPDK1±/± hearts, no signi®cant increase in PFK-2 activity
or fructose 2,6-bisphosphate levels was detected after
insulin injection.
Evidence that mPDK1±/± cardiomyocytes are more
sensitive to hypoxia
Metabolic stresses such as hypoxia leading to myocardial
injury are one of the known causes of heart failure (Hirota
et al., 1999; Cesselli et al., 2001). We therefore decided to
test whether PDK1±/± cardiomyocytes are more sensitive to
hypoxia compared with control animals. Cardiomyocytes
were isolated from mPDK1±/± and mPDK1+/+ hearts of
4-week-old mice, when signi®cant heart disease had not
yet developed (Figures 2±5). The isolated mPDK1±/±
cardiomyocytes were 40% smaller as estimated by laser
confocal microscopy (Supplementary ®gure 4), similar to
the reduction observed for cardiomyocytes in cardiac
tissue (Figure 4C). Parameters of cell viability of
mPDK1±/± cardiomyocytes including membrane potential
(Figure 7A), resting intracellular calcium concentration
([Ca2+]i) (Figure 7B) and diameter ratio (Figure 7C) were
similar to those observed for mPDK1+/+ cardiomyocytes.
Isolated mPDK1±/± and mPDK1+/+ ®eld-stimulated beating
cardiomyocytes were subjected to hypoxic conditions and
monitored continuously for [Ca2+]i and cell morphology
(Figure 7D±F). In mPDK1+/+ cardiomyocytes, hypoxia
induced intracellular Ca2+ overload associated with an
irreversible cell collapse of the rod-shape structure
(hypercontracture, leading to decrease in diameter ratio;
indicative of cell death) (JovanovicÂ et al., 1998) after
~35 min (Figure 7D±F). The beating mPDK1±/± cardio-
myocytes were markedly more sensitive to hypoxia than
mPDK1+/+ cardiomyocytes, surviving for an average of
only ~15 min (Figure 7D±G). Hypoxia did not induce
intracellular Ca2+ loading or cellular hypercontracture
when extracellular Ca2+ was removed from the extra-
cellular medium (Figure 7H) or intracellular Ca2+ stores
were blocked with thapsigargin plus ryanodine (Figure 7I).
We also performed measurements of Ca2+ transients in
mPDK1±/± and mPDK1+/+ mice in ®eld-stimulated cardio-
myocytes using laser confocal microscopy and Fluo-3
Ca2+-sensitive dye, and no differences in properties of
Ca2+ transients or cell shortening between different cell
types were observed (data not shown), suggesting that
PDK1 may not act as a negative regulator of cardiac
contractility.
To analyse whether the increased sensitivity of
mPDK1±/± cardiomyocytes to hypoxia was due to
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apoptosis, we set up a whole-heart assay in which
mPDK1±/± and mPDK1+/+ hearts were cannulated and
perfused under normoxic or hypoxic conditions for 4 h.
The activity of caspase 3, and cleavage of caspase 3,
caspase 7 and PARP protein, general markers for
apoptosis, were found to be similar in normoxic and
Fig. 7. Increased sensitivity of isolated mPDK1±/± cardiomyocytes to hypoxia. Cardiomyocytes were isolated from hearts of 4-week-old mice and pro-
cessed as described in the materials and methods (A±C) Average values of membrane potential (A), ([Ca2+]i) (B) and diameter ratio (C) of mPDK1±/±
and mPDK1+/+ cardiomyocytes. The results shown represent mean 6 SEM with measurements performed with three to eight cells of each genotype.
(D) Field stimulated beating mPDK1±/± and mPDK1+/+ cardiomyocytes were loaded with Fura 2-dye and imaged using a epi¯uorescent camera. At time
zero, to induce hypoxia, the cells were subjected to an environment of pO2 20 mmHg. Images of the cardiomyocytes were taken at the indicated time
points, and cell death is observed as a rounding up of the cardiomyocyte. (E and F) Depict time-courses of ([Ca2+]i (E) and diameter ratio (F) from
cells in (D). Arrows indicate time of cardiomyocyte death. (G) The average survival time 6 SEM of ®ve to seven different mPDK1±/± and mPDK1+/+
cardiomyocytes subjected to hypoxic conditions was quantitated. *P < 0.05. (H and I) Average values of [Ca2+]i (H) and diameter ratio (I) of mPDK1+/+
cardiomyocytes in extracellular solution without Ca2+ (Ca2+ free) or pretreated with thapsigargin plus ryanodine (Th+Ryan) prior (0 min) and after
45 min-long exposure to hypoxia. The results shown represent mean 6 SEM with measurements performed with four cells under each condition.
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hypoxic mPDK1±/± and mPDK1+/+ hearts (Supplementary
®gure 5), indicating that the mPDK1±/± hearts were not
failing due to an increase in apoptosis. As a control,
mPDK1+/+ hearts were treated with the apoptosis-inducing
non-speci®c kinase inhibitor staurosporine, which markedly
increased caspase-3 activity and the cleavage of caspase 3,
caspase 7 and PARP (Supplementary ®gure 5).
Discussion
In this study, we provide the ®rst genetic evidence that
PDK1 plays multiple roles in regulating cardiac viability.
Our analysis indicates that mPDK1±/± mice die suddenly at
an early stage of adult life, possess the same number of
smaller cardiomyocytes and develop heart failure, and that
cardiomyocytes lacking PDK1 are signi®cantly more
sensitive to hypoxia.
Mice models have previously been used to explore the
role of the PI 3-kinase pathway in heart. Mimicking the
activation of the PI 3-kinase pathway by overexpression of
active forms of PI 3-kinase-a (Shioi et al., 2000),
knockout of PTEN (Crackower et al., 2002a) and
overexpression of active PKB (Condorelli et al., 2002;
Shioi et al., 2002), resulted in an increase in the size of the
heart (hypertrophy) due to increased cell size. Conversely,
knockout of the insulin receptor (Belke et al., 2002) or the
overexpression of dominant-negative PI 3-kinase (Shioi
et al., 2000), decreased heart size (hypotrophy) by
reducing cardiomyocyte volume. A number of studies
have established that in both Drosophila and mice the PI 3-
kinase/PDK1/AGC kinase pathway plays an important
role in regulating cell size in all tissues investigated
(reviewed in Kozma and Thomas, 2002). Consistent with
this notion, we have also shown that mouse embryonic
endoderm cells lacking PDK1 have a 60% reduced
cytoplasmic volume (Lawlor et al., 2002). Moreover,
PDK1 hypomorphic mice that express only 10% of the
normal level of PDK1 are ~40% smaller, and our analysis
indicated this was due to these animals possessing smaller
cells (Lawlor et al., 2002). In agreement with the notion
that PDK1 plays a major role in regulating cell volume, we
show that mPDK1±/± hearts are smaller, as a consequence
of decreased cardiomyocyte size (Figures 2 and 4;
Supplementary ®gure 4). At present, it is not possible to
conclude whether it is the lack of activation of PKB, S6K
or another PDK1 substrate that mediates the reduction in
cardiomyocyte volume in mPDK1±/± mice. The knockouts
thus far described for PKBa (Chen et al., 2001b; Cho et al.,
2001b), PKBb (Cho et al., 2001a) and S6K1 (Shima et al.,
1998) were not reported to reduced heart size or cardiac
phenotype, but this could be due to the presence of other
isoforms of these kinases. PKB was assessed to play a
central role in regulating cardiac size based on the results
obtained with mice overexpressing 10- to 30-fold higher
PKB levels than found physiologically (Condorelli et al.,
2002; Shioi et al., 2002). However, it should be pointed
out that a decrease in cell size in the PDK1 hypomorphic
mice occurred under conditions where insulin was able to
trigger normal activation of PKB and S6K (Lawlor et al.,
2002), suggesting that PDK1 may regulate cell size
independently of PKB and S6K.
In contrast to other genetic models of the PI 3-kinase
pathway generated thus far, the mPDK1±/± mice are the
only ones that develop cardiomyopathy leading to death in
early adulthood. One of the reasons for this could be that
the smaller mPDK1±/± hearts are not able to properly ful®l
necessary cardiac function in adult mice. The mPDK1±/±
mice ful®l the main criteria to support the diagnosis of
heart failure. This includes marked thinning of ventricular
walls assessed by both histological and echocardiographic
analysis, contractile dysfunction assessed by echocardio-
graphy, separation of cardiomyocytes within cardiac
tissue, increased collagen content, abnormal expression
of embryonic genes and an increase in Z-line thickness
prior to death. The ®ndings that the myo®brils are not
disorganized in the mPDK1±/± mice (Supplementary
®gure 3), that the ventricle walls are thinner (Figures 2
and 3) and that p38 activation in hearts of mPDK1±/± mice
is reduced (Fig 5C) argues against hypertrophy.
Previously, cardiac hypotrophy was observed in mice
lacking the insulin receptor (Belke et al., 2002) or
overexpressing dominant-negative PI 3-kinase (Shioi
et al., 2000), but the mice did not develop heart failure.
The main difference between these models and the
mPDK1±/± mice is that the activity of PKB, S6K and
probably other PDK1-regulated AGC kinase substrates are
totally ablated in mPDK1±/± hearts. PDK1 hypomorphic
mice possess markedly hypotrophic hearts (A.Mora and
A.JovanovicÂ, unpublished data), but did not develop heart
failure (Lawlor et al., 2002). A key role for the PKB
pathway is to suppress apoptosis, and therefore the
development of heart failure in mPDK1±/± mice could
have resulted from increased apoptotic cell death. Our data
would argue against this, as the number of cardiomyocytes
in mPDK1+/+ and mPDK1±/± hearts is similar (Figure 4B),
and by the ®nding that markers of apoptosis (caspase 3,
cleavage of caspase 3,caspase 7 and PARP) are not
elevated in mPDK1±/± hearts (Supplementary ®gure 5).
In humans, one of the major causes of heart failure is
ischaemic heart disease associated with hypoxia (Hirota
et al., 1999; Cesselli et al., 2001). Work carried out over
the last 15 years has demonstrated that ischaemia/hypoxia
activates signalling pathways that enable cardiomyocytes
to survive under these adverse conditions (Sugden and
Clerk, 1998; Marber, 2000). Previous studies employing
inhibitors of PI 3-kinase and overexpression of constitu-
tively active or dominant-negative mutants of PI 3-kinase
and PKB, in general, support the conclusion that this
pathway plays a role in promoting survival in hypoxic and
other stressful conditions (Fujio et al., 2000; Chen et al.,
2001a; Jonassen et al., 2001; Baines et al., 2002). In the
present study, we have used ®eld-stimulated beating
cardiomyocytes to directly measure the effect that lack
of PDK1 has on resistance to hypoxia. We employed this
approach as single cardiomyocytes are free of hormonal,
neuronal and vascular in¯uences, and thus any difference
between control and mPDK1±/± myocytes can be ascribed
reliably to the absence of PDK1. Bearing in mind that the
initial metabolic condition of a cardiomyocyte may
determine the outcome of a stress (JovanovicÂ et al.,
1996), it is important to note that mPDK1±/± and
mPDK1+/+ cardiomyocytes had similar parameters of cell
viability at rest (Figure 7A±C). We found that mPDK1±/±
cardiomyocytes were considerably more sensitive to
hypoxia than control mPDK1+/+ cardiomyocytes
(Figure 7). In previous studies, it has been shown that
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`chemical' hypoxia induces necrotic cell death by increas-
ing intracellular Ca2+ via mechanisms that involve both
extracellular and intracellular Ca2+ pools (JovanovicÂ and
JovanovicÂ, 2001). In addition to these studies, we now
provide evidence that extracellular Ca2+ as well as Ca2+
stored in subcellular compartments contribute to Ca2+
overload under `genuine' hypoxia. We show that removal
of extracellular Ca2+ throughout hypoxia can abolish Ca2+
loading as well as treatment with agents that deplete or
inhibit intracellular Ca2+ stores (Figure 7H and I). Thus,
Ca2+ loading following hypoxia of cardiomyocytes may
have occurred through in¯ux and release of Ca2+ from
intracellular stores. Whole-heart experiments suggest a
necrotic nature of hypoxia-induced cell death rather than
apoptotic (Supplementary ®gure 5).
Although we have provided evidence for a role of PDK1
in promoting cardiomyocyte survival and preventing heart
failure, it should be noted that further research is required
to establish whether the increased sensitivity of mPDK1±/±
cardiomyocytes to metabolic stresses (Figure 7) con-
tributes to the development of heart failure in mPDK1±/±
mice. Moreover, we have shown that in mPDK1±/± hearts,
PFK-2 cannot be activated by insulin (Figure 6E and F),
which would prevent the stimulation of glycolysis by
insulin. The loss of the stimulation of glycolysis by insulin
could modify the regulation of the fuel hierarchy by this
hormone and such disruption could contribute to onset of
heart failure in mPDK1±/± mice. It has to be noted that
insulin, in combination with glucose and potassium, exerts
a protective effect on the ischaemic heart by reducing
infarct size and improving post-ischaemic left ventricular
function. Even if the exact role of insulin remains unclear,
the cardiac protection conferred by the hormone appears
when the coronary ¯ow is restored and may be related to
the metabolic effect favouring glucose utilization instead
of fatty acid oxidation (Beauloye et al., 2001; Hue et al.,
2002). The loss of this bene®cial effect of insulin could
also contribute to the heart phenotype of mPDK1±/± mice.
In conclusion, we have provided ®rm genetic evidence
that PDK1 regulates heart growth and viability. Moreover,
we also show that PDK1 is necessary for the activation of
PFK-2 and production of fructose 2,6-bisphosphate in-
duced by insulin, and provide evidence that PDK1 is
implicated in cardioprotective signalling. Taken together,
the data presented in this study suggest that cardiomyo-
pathies resulting in ventricular thinning and dilatation and
ischaemic heart disease in humans could perhaps be
treated by strategies that trigger the activity of PDK1.
Materials and methods
Materials and methods are presented as Supplementary data available at
The EMBO Journal Online.
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